Document text
Principal Investigator: Bronwyn Mei Gunn
Organization: WASHINGTON STATE UNIVERSITY
Fiscal Year: 2024
Award: $183,960
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY
Antibodies are critical mediators of immune protection against pathogens, simultaneously acting to neutralize
entry and activate innate immune cells through interaction between the antibody Fc domain and Fc-receptors
(FcRs) on innate immune cells. Leveraging Fc-mediated activation in monoclonal antibody-based therapies is
increasingly being investigated for the treatment of infectious diseases but the precise mechanisms and breadth
of functions that can be induced by range of FcR-bearing immune cells is still unclear. However, these efforts
are limited by the fact that we do not fully understand the spectrum of effector functions and effector programs
that are induced via different FcRs, which could greatly impact efficacy and safety of mAb-based therapeutics.
Moreover, as some innate immune cells such as monocytes express multiple FcRs, understanding how these
pathways interact will help in the development of rational antibody design strategies to effectively harness innate
immune cells against a variety of pathogens.
There are four activating FcRs that bind IgG and are expressed on innate immune cells (FcγR1, FcγR2A,
FcγR3A, and FcγR3B) and one inhibitory receptor (FcγR2B). The interplay between these receptors can impact
Fc-effector functions, especially in monocytes that express multiple FcRs. Moreover, antibody-mediated
activation of non-classical monocytes that express 3 activating FcγRs must balance protection and pathology,
as antibody-dependent enhancement of infection/disease has been observed in some contexts. Thus, defining
the transcriptional profiles of FcR-mediated activation of will be critical to better predict in vivo activity of
immunotherapies and antibodies induced by vaccination or infection. To that end, we propose to begin to
generate an ‘FcR Effector Atlas’ that defines the anti-pathogen pathways that are induced in distinct innate
immune cell types mediated by different FcRs. The Atlas can be used to map the pathways induced across all
innate immune cells to help guide development of optimally efficacious and safe antibody therapeutics against
infectious diseases.
By combining Fc-engineered antibodies that facilitate individual or combinatorial activation of specific FcRs
and nascent transcriptomics, the goal of this proposal is pioneer an approach to generate the Atlas in
nonclassical monocytes. We will use SARS-CoV-2-specfic Fc-engineered monoclonal antibodies as a model
system to specifically engage different FcRs on monocytes to define the FcR-mediated transcriptional network
using capped small RNA-sequencing (csRNA-seq) that enables transcriptional profiling of nascent RNA
transcriptional start sites. Further, we will functionally link induction of specific pathways to restriction of SARS-
CoV-2 infection. Together, the approaches and results generated from this proposal will contribute to our
fundamental understanding of how antibodies leverage innate immunity and can be used to guide development
of highly effective and safe immunotherapeutics for infectious diseases and beyond.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><AP-1><AP-1 Enhancer-Binding Protein><AP1><AP1 protein><Activator Protein-1><Affinity><Anti-viral Response><Antibodies><Antibody Activation><Antibody Therapy><Antibody-Dependent Enhancement><Atlases><Basal Transcription Factor><Basal transcription factor genes><Biologic Models><Biological Models><Biological Response Modifiers><Biomodulators><Blood monocyte><COVID-19 infection><COVID-19 virus><COVID-19 virus infection><COVID19 infection><COVID19 virus><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Clinical Treatment Moab><Closure by Ligation><CoV-2><CoV2><Communicable Diseases><Development><Disease><Disorder><EBOV><Ebola virus><Ebola-like Viruses><Engineering><Enhancer-Binding Protein AP1><Equilibrium><Event><Expression Signature><Fc Receptor><Fc domain><Foundations><Future><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profile><Gene Expression Profiling><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Transcription><Goals><Homolog of Drosophila TOLL><Hour><Human><IgA><IgG><Immune><Immune Mediators><Immune Mediators/Modulators><Immune Regulators><Immune mediated therapy><Immune system><Immunes><Immunity><Immunoglobulin A><Immunoglobulin G><Immunologically Directed Therapy><Immunotherapeutic agent><Immunotherapy><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inflammation><Innate Immunity><Intracellular Communication and Signaling><Kinetics><Knowledge><Ligation><Link><MAb Therapeutics><Maps><Marrow monocyte><Mediating><Model System><Modeling><Modern Man><Monoclonal Antibodies><Monoclonal Antibody Therapy><Native Immunity><Natural Immunity><Non-Polyadenylated RNA><Non-Specific Immunity><Nonspecific Immunity><Pathology><Pathway interactions><Play><RNA><RNA Expression><RNA Gene Products><RNA Seq><RNA sequencing><RNAseq><Receptor Protein><Regulatory Pathway><Research><Ribonucleic Acid><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 infection><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Shapes><Signal Transduction><Signal Transduction Systems><Signaling><Small RNA><TLR4><TLR4 gene><Therapeutic><Therapeutic Monoclonal Antibodies><Therapeutic antibodies><Toll Homologue><Transcript Expression Analyses><Transcript Expression Analysis><Transcription><Transcription Activation><Transcription Factor AP-1><Transcription Factor Proto-Oncogene><Transcription Initiation Site><Transcription Start Site><Transcription factor genes><Transcriptional Activation><Translating><Vaccination><Viral><Viral Diseases><Virus Diseases><Work><Wuhan coronavirus><analyze gene expression><antibody based therapies><antibody engineering><antibody receptor><antibody treatment><antibody-based therapeutics><antibody-based treatment><balance><balance function><biological signal transduction><cell type><combinatorial><coronavirus disease 2019 infection><coronavirus disease 2019 virus><coronavirus disease-19 virus><design><designing><developmental><gene expression analysis><gene expression assay><gene expression pattern><gene expression signature><hCoV19><immune drugs><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunologic therapeutics><immunomodulatory biologics><immunotherapeutics><immunotherapy agent><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infectious disease treatment><innate immune mechanisms><mAB-based therapy><mAb therapy><mAb-based therapeutics><mAbs><monoclonal Abs><monoclonal antibody drugs><monocyte><nCoV2><new approaches><novel approaches><novel strategies><novel strategy><pathogen><pathway><programs><receptor><receptor binding><receptor bound><social role><therapeutic mAbs><toll-like receptor 4><tool><transcription factor><transcriptional profile><transcriptional profiling><transcriptional signature><transcriptome sequencing><transcriptomic sequencing><transcriptomics><vaccine response><vaccine responsiveness><vaccine-induced response><viral infection><virus infection><virus-induced disease>